Full Breakdown
Fatalities Linked to Bootleg Retatrutide Highlight Growing Illicit Market Risks
By Drooid · · How we work
Fatalities Linked to Bootleg Retatrutide
The U.S. Food and Drug Administration (FDA) received two adverse event reports involving deaths after use of unapproved, bootleg retatrutide, an experimental weight-loss drug from Eli Lilly. The first case, reported in July, involved a 41-year-old woman with obesity who suffered cardiac arrest after obtaining the product from an “unreliable source.” The second case, reported in September, described a 49-year-old patient who purchased the drug from an online peptide vendor after a licensed nurse provided a link and dosing instructions; the patient later experienced severe dehydration, malnutrition and cardiac arrest. Both reports were submitted to the FDA’s Adverse Event Reporting System.
Background & Context
Retatrutide is a triple-agonist that activates GLP-1, GIP and glucagon receptors and remains in Phase 3 trials (TRIUMPH-2). Despite its investigational status, the drug is advertised on health-spa websites and wellness platforms, and vendors often label it “for research use only” while consumers purchase it for personal injection. The illicit market has expanded rapidly, with dozens of online sellers offering lyophilized powder at $50-$300 per vial.
Data & Statistics
- America’s Poison Centers recorded 862 exposures to retatrutide in the three months ending September 2026, up from 460 in the preceding three-month period.
- Clinical trials have shown retatrutide can produce weight loss exceeding that of existing GLP-1 agents, fueling high public demand.
- U.S. Customs and Border Protection intercepted more than 690 shipments containing over 31,000 units of illicit GLP-1 drugs in fiscal 2025.
Official Statements & Responses
Sinead Killeen, attorney for Alpha Labs owner Joseph Samara, expressed sympathy for the families while noting the FDA report lacked detail to confirm Alpha Labs’ involvement.
Jayne Hornung, chief clinical officer for Norstella’s MMIT, warned that the scale of black-market sales could present a novel challenge for Lilly at product launch.
Conflicting Reports & Gaps
- The FDA has not verified causality between the bootleg product and the deaths; the redacted reports lack batch numbers or definitive chemical analyses.
- Eli Lilly attributes the fatalities to black-market versions, but agency records do not confirm the composition of the injected material.
- The nurse’s role described in the September report remains unverified; the nurse’s identity and licensing details were redacted, and no disciplinary action has been reported.
Verbatim Quotes
- “It is concerning because of the breakdown of our drug-approval process in the United States of America,” — Pieter Cohen, associate professor, Harvard Medical School
- “We extend our sympathies to the family of the individual described in the report," Killeen wrote.” — Sinead Killeen, attorney representing Samara
- “Unfortunately, Lilly is going to face something we've never seen at launch before,” — Jayne Hornung, chief clinical officer, Norstella’s MMIT
What’s Next
Eli Lilly plans to file a New Drug Application for retatrutide with the FDA in the first quarter of 2027. The company continues to refer suspected illegal sellers to law-enforcement agencies and has reported more than 14,000 online listings to internet service providers. The FDA indicated it will keep reviewing adverse event submissions and may pursue compliance actions, though no specific timeline has been disclosed.